Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1.

In a secondary analysis of AtezoTRIBE, in which 75% of participants had LM, a highly significant association of the presence of LM was again seen, even after adjusting for RAS and BRAF status. 25 However, in the setting of multiagent chemotherapy and bevacizumab, IS-IC retains its predictive power for the addition of anti-PD-L1 in the subset of patients with pMMR CRC with LM.

also in 132,142 other papers